Cargando…
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, has attracted interest as a target for pharmacological intervention in malignant diseases. Here, we describe BI 853520, a novel ATP-competitive inhibitor distinguished by high potency and selectivity. In vitro, the compound inhibits FAK au...
Autores principales: | Hirt, Ulrich A., Waizenegger, Irene C., Schweifer, Norbert, Haslinger, Christian, Gerlach, Daniel, Braunger, Jürgen, Weyer-Czernilofsky, Ulrike, Stadtmüller, Heinz, Sapountzis, Ioannis, Bader, Gerd, Zoephel, Andreas, Bister, Bojan, Baum, Anke, Quant, Jens, Kraut, Norbert, Garin-Chesa, Pilar, Adolf, Günther R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833389/ https://www.ncbi.nlm.nih.gov/pubmed/29472531 http://dx.doi.org/10.1038/s41389-018-0032-z |
Ejemplares similares
-
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
por: Tiede, Stefanie, et al.
Publicado: (2018) -
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018) -
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
por: Gerlach, Daniel, et al.
Publicado: (2018) -
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
por: de Jonge, Maja J. A., et al.
Publicado: (2019) -
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)